The treatment of wet age-related macular degeneration;Therapie der feuchten altersbedingten makuladegeneration

Deutsches Arzteblatt

Volumn 106, Issue 18, 2009, Pages 312-317

  Joussen, Antonia M ^a   Bornfeld, Norbert ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Age related macular degeneration; Macular degeneration; Monoclonal antibodies; Off label treatment; Treatment

Indexed keywords

ANECORTAVE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CISPLATIN; DEXAMETHASONE; HYPOXIA INDUCIBLE FACTOR 1; PACLITAXEL; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; POLYAMINE; RANIBIZUMAB; SMALL INTERFERING RNA; STEROID; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ADVANCED CANCER; ANGIOGRAPHY; ARGON PLASMA COAGULATION; BLOOD VESSEL OCCLUSION; BREAST CANCER; BRUCH MEMBRANE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CARCINOMA; CORNEA DISEASE; CORNEA TRANSPLANTATION; DIET SUPPLEMENTATION; DRUG INFORMATION; DRUG MEGADOSE; DRUSEN; ENDOPHTHALMITIS; EXTRACELLULAR MATRIX; FLUID TRANSPORT; FLUORESCENCE ANGIOGRAPHY; GERMANY; HEALTH INSURANCE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNET; ION TRANSPORT; KIDNEY CANCER; LENS DISEASE; LUNG CARCINOMA; LUNG METASTASIS; MEDICAL SOCIETY; MYOPIA; NONHUMAN; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATHOGENESIS; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PROGNOSIS; PROSPECTIVE STUDY; QUESTIONNAIRE; REIMBURSEMENT; REPEAT PROCEDURE; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA TEAR; REVIEW; RISK ASSESSMENT; STROKE; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT INDICATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMANS; LIGHT COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY;

EID: 69049102036     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0312     Document Type: Review

References (24)

1. Spiro T: Luc(ifer)entis. Dtsch Arztebl 2007; 104(28-29): A2033.
2. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM: The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995; 36: 182-191
3. Schrader WF: Altersbedingte Makuladegeneration: eine sozioö konomische Zeitbombe in unserer alternden Gesellschaft. Ophthalmologe 2006; 103: 742-748
4. Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP: Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br J Ophthalmol 1999; 83: 358-368
5. de Jong PT: Age-related macular degeneration. N Engl J Med 2006; 355: 1474-1485
6. Pauleikhoff D, Bornfeld N, Gabel VP, Holz F, Roider H: Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte - Stellungnahme zur aktuellen Therapie der neovaskulären AMD. Klin Monatsbl Augenheilkd 2005; 222: 381-388 (Pubitemid 40825851)
7. Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular agerelated macular degeneration. Klin Monatsbl Augenheilkd 2007; 224: 559-566
8. Wormald R, Evans J, Smeeth L, Henshaw K: Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2005 Oct 19; (4): CD002030.
9. Review. Update in: Cochrane Database Syst Rev. 2007; (3): CD002030.
10. Folkman J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972; 175: 409-416
11. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS et al.: Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-584 (Pubitemid 24285965)
12. Chakravarthy U, Adamis AP, Cunningham ET Jr. et al.: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508 e1-e25.
13. Jaissle GB, Szurman P, Bartz-Schmidt KU: Empfehlung für die Durchführung von intravitrealen Injektionen - Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft (DOG) und des Berufsverbands der Augenärzte Deutschland (BVA). Klin Monatsbl Augenheilkd 2005; 222: 390-395 (Pubitemid 40825853)
14. Brown DM, Kaiser PK, Michels M et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444 (Pubitemid 44511558)
15. Rosenfeld PJ, Brown DM, Heier JS et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431 (Pubitemid 44511557)
16. Heiduschka P, Fietz H, Hofmeister S et al.: Tübingen Bevacizumab Study Group: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823
17. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372 e5.
18. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F: A systematic review on the effect of bevacizumab in exudative agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1-11.
19. Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349
20. Chan CK, Meyer CH, Gross JG et al.: Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27: 541-551 (Pubitemid 46905143)
21. Bakri SJ, Kitzmann AS: Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 2007; 143: 505-507 (Pubitemid 46273349)
22. Bressler SB, Childs AL, Haller JA et al.: Submacular Surgery Trials (SST) Research Group: Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology 2004; 111: 1993-2006.
23. Kim I, Ryan AM, Rohan R et al.: Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40: 2115-21. Erratum in: Invest Ophthalmol Vis Sci 2000; 41: 368.
24. Lux A, Llacer H, Heussen FM, Joussen AM: Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007; 91: 1318-1322 (Pubitemid 47492865)